INTEGRATIVE BIOINFORMATICS APPROACHES TO THE UNDERSTANDING OF CHRISTININ MOLECULAR MECHANISM AS JANUS KINASE (JAK) INHIBITORS FOR SUPPRESSING HYPERINFLAMMATION IN COVID-19

COVID-19 is a significant worldwide health concern. The exaggerated immune response known as the "cytokine storm" is a key factor in this illness, and there are potential ways to address it. Janus kinase (JAK) inhibitors are a type of medication that might reduce inflammation and improve t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rasāyan journal of chemistry 2024-04, Vol.17 (2), p.425-435
Hauptverfasser: F. Darusman, Fakih, T.M., Ramadhan, D.S.F.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:COVID-19 is a significant worldwide health concern. The exaggerated immune response known as the "cytokine storm" is a key factor in this illness, and there are potential ways to address it. Janus kinase (JAK) inhibitors are a type of medication that might reduce inflammation and improve the body's production of antibodies. Pharmacokinetic profiles, toxicity characteristics, biological activities prediction, and molecular docking simulation will be conducted to discover, assess, and investigate the molecular interactions of Christinin compounds, including Christinin-A, Christinin-B, Christinin-C, and Christinin-D derived from Ziziphus spina-christi leaves as Janus kinase (JAK) inhibitors using bioinformatics approaches. Based on the molecular docking simulation, it can be concluded that the Christinin compound has a molecular interaction with Janus Kinase (JAK). However, Christinin-A and Christinin-C compounds have better affinity than Christinin-B and Christinin-D compounds, with binding free energy values of −7.59 kcal/mol and −5.37 kcal/mol, respectively. Therefore, these two compounds can be used as candidates for Janus Kinase (JAK) inhibitors in preventing hyperinflammation in the COVID-19 infectious disease
ISSN:0974-1496
0974-1496
DOI:10.31788/RJC.2024.1728340